News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG to Host Scientific Webinar Featuring Customer Use of the HTG Transcriptome Panel in Preclinical and Clinical Programs
TUCSON, Ariz. , June 01, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be hosting a scientific webinar titled “Integration of
View HTML
Toggle Summary HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference
TUCSON, Ariz. , May 17, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C.
View HTML
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2022 Results
Call scheduled for today, May 12, at 4:30 pm ET TUCSON, Ariz. , May 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Q1 2022 Financial Results and Host Conference Call on Thursday, May 12
TUCSON, Ariz. , May 05, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended
View HTML
Toggle Summary HTG Expands Therapeutics Team
Christina M. Carruthers, Ph.D. Joins as Vice President of Target Strategy and Early Development TUCSON, Ariz. , April 13, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide
View HTML
Toggle Summary HTG Expands Features of Proprietary HTG EdgeSeq Technology
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample TUCSON, Ariz. , April 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative
View HTML
Toggle Summary HTG Releases Proof-of-Approach Whitepaper Establishing Utility of Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz. , March 31, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”),
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Full Year 2021 Results
Call scheduled for today, March 29, at 4:30 pm ET TUCSON, Ariz. , March 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Year End 2021 Financial Results and Host Conference Call on Tuesday, March 29
TUCSON, Ariz. , March 22, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the year ended
View HTML
Toggle Summary HTG Molecular Diagnostics Announces $7.5 Million Private Placement
TUCSON, Ariz. , March 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private
View HTML